Immutep to Present at Investor Conferences
May 20, 2022 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, May 20, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy...
Immutep Appoints Leading Oncologists to its Clinical Advisory Board
May 18, 2022 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, May 18, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy...
Immutep Presents New and Significant Data from the AIPAC Study
May 04, 2022 08:00 ET
|
Immutep Limited
Statistically significant increase in innate and adaptive immune response biomarkers (monocyte and CD8 T cell counts and serum CXCL10 levels) and absolute lymphocyte count (ALC) demonstrated in the...
Immutep Quarterly Activities Report
April 29, 2022 08:00 ET
|
Immutep Limited
New interim TACTI-002 data from 2nd line metastatic non-small cell lung carcinoma (NSCLC) patients shows encouraging early overall survival rate of 73.7% at the six-month landmarkConstructive feedback...
Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual Meeting
April 28, 2022 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, April 28, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy...
Immutep’s Efti in Combination with MSD’s Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2nd Line Metastatic Lung Cancer Patients
March 30, 2022 08:00 ET
|
Immutep Limited
All enrolled patients were 2nd line metastatic non-small cell lung carcinoma (NSCLC) patients that had confirmed progressive disease after prior PD-1 or PD-L1 therapy (PD-X refractory)Encouraging...
Immutep Announces Publication of TACTI-002 Abstract at ESMO’s European Lung Cancer Congress 2022
March 24, 2022 08:00 ET
|
Immutep Limited
New interim data from TACTI-002 (Part B) evaluating the combination of efti and pembrolizumab in 2nd line, confirmed PD-1/PD-L1 refractory, non-small cell lung cancer (NSCLC) patientsCombination...
Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525
March 18, 2022 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, March 18, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce the grant of patent no. 7030750 entitled...
Immutep To Present Biomarker And Multivariate Analysis From Phase IIb AIPAC Study In Metastatic Breast Cancer At ESMO’s Breast Cancer Congress 2022
March 18, 2022 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, March 18, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce new biomarker and multivariate analysis data from...
Immutep Receives Constructive Feedback from US FDA on its Clinical Development Program for EFTI in Metastatic Breast Cancer
March 10, 2022 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, March 10, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce it has received constructive feedback from the US...